155 related articles for article (PubMed ID: 27903863)
1. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Thorek DL; Watson PA; Lee SG; Ku AT; Bournazos S; Braun K; Kim K; Sjöström K; Doran MG; Lamminmäki U; Santos E; Veach D; Turkekul M; Casey E; Lewis JS; Abou DS; van Voss MR; Scardino PT; Strand SE; Alpaugh ML; Scher HI; Lilja H; Larson SM; Ulmert D
Sci Transl Med; 2016 Nov; 8(367):367ra167. PubMed ID: 27903863
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
3. Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response.
Storey CM; Altai M; Bicak M; Veach DR; Lückerath K; Adrian G; McDevitt MR; Kalidindi T; Park JE; Herrmann K; Abou D; Zedan W; Peekhaus N; Klein RJ; Damoiseaux R; Larson SM; Lilja H; Thorek D; Ulmert D
Mol Cancer Res; 2023 Apr; 21(4):307-315. PubMed ID: 36608299
[TBL] [Abstract][Full Text] [Related]
4. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.
McDevitt MR; Thorek DLJ; Hashimoto T; Gondo T; Veach DR; Sharma SK; Kalidindi TM; Abou DS; Watson PA; Beattie BJ; Timmermand OV; Strand SE; Lewis JS; Scardino PT; Scher HI; Lilja H; Larson SM; Ulmert D
Nat Commun; 2018 Apr; 9(1):1629. PubMed ID: 29691406
[TBL] [Abstract][Full Text] [Related]
5. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
6. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
7. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
8. The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.
Tabrizipour AI; Dunne M
Clin Nucl Med; 2015 May; 40(5):e285-6. PubMed ID: 25608148
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer With Isolated Bony Metastasis: Sternal Struggle.
Corkum MT
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):492-493. PubMed ID: 28581385
[No Abstract] [Full Text] [Related]
10. Distant metastases from prostatic carcinoma express androgen receptor protein.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Cancer Res; 1995 Jul; 55(14):3068-72. PubMed ID: 7541709
[TBL] [Abstract][Full Text] [Related]
11. Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.
Timmermand OV; Ulmert D; Evans-Axelsson S; Pettersson K; Bjartell A; Lilja H; Strand SE; Tran TA
EJNMMI Res; 2014 Dec; 4(1):51. PubMed ID: 26116115
[TBL] [Abstract][Full Text] [Related]
12. 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET).
Bertolini R; Goepfert C; Andrieu T; Nichols S; Walter MA; Frey FJ; McCammon JA; Frey BM
Prostate; 2015 Mar; 75(4):348-59. PubMed ID: 25358634
[TBL] [Abstract][Full Text] [Related]
13. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells.
He ML; Yuan HQ; Jiang AL; Gong AY; Chen WW; Zhang PJ; Young CY; Zhang JY
Cancer; 2006 Jun; 106(12):2547-55. PubMed ID: 16691616
[TBL] [Abstract][Full Text] [Related]
14. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
Fisher TL; Nocera M; Willis RA; Turner MJ; Abdul Alim CS; Brown DM; Bourne PA; di Sant'Agnese PA; Messing EM; Lord EM; Frelinger JG
Prostate; 2002 May; 51(3):153-65. PubMed ID: 11967950
[TBL] [Abstract][Full Text] [Related]
15. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
Xie X; Zhao X; Liu Y; Young CY; Tindall DJ; Slawin KM; Spencer DM
Hum Gene Ther; 2001 Mar; 12(5):549-61. PubMed ID: 11268287
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies.
Han G; Kortylewicz ZP; Enke T; Baranowska-Kortylewicz J
Prostate; 2014 Dec; 74(16):1634-46. PubMed ID: 25214432
[TBL] [Abstract][Full Text] [Related]
18. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.
Kang HY; Huang HY; Hsieh CY; Li CF; Shyr CR; Tsai MY; Chang C; Chuang YC; Huang KE
J Bone Miner Res; 2009 Jul; 24(7):1180-93. PubMed ID: 19257827
[TBL] [Abstract][Full Text] [Related]
19. Positron tomographic assessment of androgen receptors in prostatic carcinoma.
Dehdashti F; Picus J; Michalski JM; Dence CS; Siegel BA; Katzenellenbogen JA; Welch MJ
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):344-50. PubMed ID: 15726353
[TBL] [Abstract][Full Text] [Related]
20. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
